Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLGN NASDAQ:COCH NASDAQ:LFWD NASDAQ:PSTV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLGNCollPlant Biotechnologies$2.33-3.7%$1.91$1.31▼$5.45$30.77M1.4564,108 shs20,491 shsCOCHEnvoy Medical$1.45-1.0%$1.51$1.21▼$3.99$31.14M2.2127,995 shs4,272 shsLFWDLifeward$0.70-1.0%$0.91$0.50▼$4.29$7.74M0.09564,050 shs217,717 shsPSTVPlus Therapeutics$0.59+21.1%$0.35$0.16▼$2.31$29.22M0.6718.29 million shs12.19 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLGNCollPlant Biotechnologies-3.72%+0.87%+64.08%+8.88%-45.56%COCHEnvoy Medical-1.03%-7.37%-3.67%+6.64%-32.48%LFWDLifeward-1.00%-10.14%+3.52%-50.61%-84.79%PSTVPlus Therapeutics+21.12%+10.42%+90.43%-9.71%-67.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLGNCollPlant Biotechnologies2.14 of 5 stars3.73.00.00.00.00.00.6COCHEnvoy Medical1.9349 of 5 stars3.52.00.00.00.43.30.0LFWDLifeward1.7659 of 5 stars3.52.00.00.00.60.01.3PSTVPlus Therapeutics2.194 of 5 stars3.34.00.00.02.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLGNCollPlant Biotechnologies 3.33Buy$11.50393.56% UpsideCOCHEnvoy Medical 3.00Buy$9.25540.14% UpsideLFWDLifeward 3.00Buy$9.001,192.36% UpsidePSTVPlus Therapeutics 2.50Moderate Buy$10.831,751.85% UpsideCurrent Analyst Ratings BreakdownLatest LFWD, COCH, PSTV, and CLGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025PSTVPlus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.50 ➝ $3.006/25/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold$9.006/5/2025PSTVPlus TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $20.505/28/2025CLGNCollPlant BiotechnologiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.005/27/2025COCHEnvoy MedicalAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.25 ➝ $9.505/5/2025PSTVPlus TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/5/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLGNCollPlant Biotechnologies$510K58.11N/AN/A$1.18 per share1.97COCHEnvoy Medical$220K140.10N/AN/A($0.88) per share-1.64LFWDLifeward$25.66M0.30N/AN/A$2.14 per share0.33PSTVPlus Therapeutics$5.82M6.08N/AN/A($1.52) per share-0.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLGNCollPlant Biotechnologies-$16.61M-$1.22N/AN/AN/A-560.92%-87.33%-65.31%8/19/2025 (Estimated)COCHEnvoy Medical-$20.80M-$1.38N/AN/AN/A-10,961.26%N/A-233.08%8/11/2025 (Estimated)LFWDLifeward-$28.94M-$3.04N/AN/AN/A-108.21%-101.96%-70.49%8/13/2025 (Estimated)PSTVPlus Therapeutics-$12.98M-$2.94N/AN/AN/A-520.90%N/A-202.73%8/13/2025 (Estimated)Latest LFWD, COCH, PSTV, and CLGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025CLGNCollPlant Biotechnologies$0.29N/AN/AN/A$8.91 millionN/A8/13/2025Q2 2025LFWDLifeward-$0.25N/AN/AN/A$6.62 millionN/A8/13/2025Q2 2025PSTVPlus Therapeutics-$0.12N/AN/AN/A$1.08 millionN/A8/11/2025N/ACOCHEnvoy Medical-$0.30N/AN/AN/AN/AN/A7/31/2025Q2 2025COCHEnvoy Medical-$0.29-$0.32-$0.03-$0.32$0.07 million$0.08 million6/4/2025Q1 2025CLGNCollPlant Biotechnologies-$0.37-$0.13+$0.24-$0.13$9.76 million$2.06 million5/30/2025Q1 2025PSTVPlus Therapeutics-$0.17-$0.56-$0.39-$1.19$1.11 million$1.06 million5/15/2025Q1 2025LFWDLifeward-$0.33-$0.46-$0.13-$0.46$5.84 million$5.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLGNCollPlant BiotechnologiesN/AN/AN/AN/AN/ACOCHEnvoy MedicalN/AN/AN/AN/AN/ALFWDLifewardN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLGNCollPlant BiotechnologiesN/A4.484.23COCHEnvoy MedicalN/A1.090.88LFWDLifewardN/A2.181.43PSTVPlus TherapeuticsN/A1.031.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLGNCollPlant Biotechnologies21.69%COCHEnvoy Medical8.59%LFWDLifeward26.76%PSTVPlus Therapeutics3.28%Insider OwnershipCompanyInsider OwnershipCLGNCollPlant Biotechnologies9.60%COCHEnvoy Medical58.90%LFWDLifeward2.70%PSTVPlus Therapeutics0.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLGNCollPlant Biotechnologies7012.72 million11.50 millionOptionableCOCHEnvoy Medical3421.33 million8.77 millionNot OptionableLFWDLifeward6011.01 million10.71 millionOptionablePSTVPlus Therapeutics2060.49 million60.01 millionNot OptionableLFWD, COCH, PSTV, and CLGN HeadlinesRecent News About These CompaniesPlus Therapeutics Provides US Launch Update for its CNSide® DiagnosticJuly 31 at 7:30 AM | globenewswire.comPlus Therapeutics (NASDAQ:PSTV) Stock Rating Lowered by Wall Street ZenJuly 28, 2025 | americanbankingnews.comPlus Therapeutics, Inc. Secures $1.6 Million Advance Payment from CPRIT to Support CNS Cancer Research and DevelopmentJuly 23, 2025 | quiverquant.comQPlus Therapeutics Announces $1.6 Million Advance Payment from CPRITJuly 23, 2025 | globenewswire.comPlus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal MetastasesJuly 15, 2025 | finance.yahoo.comPlus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal MetastasesJuly 15, 2025 | globenewswire.comPlus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases ConferenceJuly 10, 2025 | globenewswire.comPlus Therapeutics Initiates ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases TreatmentJuly 8, 2025 | quiverquant.comQPlus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal MetastasesJuly 8, 2025 | globenewswire.comPSTV - Plus Therapeutics Inc Trailing Returns - MorningstarJuly 2, 2025 | morningstar.comMPlus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal MetastasesJune 30, 2025 | globenewswire.comPlus Therapeutics Provides Business Update on CNSide Diagnostics SubsidiaryJune 26, 2025 | globenewswire.comPlus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ETJune 25, 2025 | globenewswire.comPlus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain CancerJune 25, 2025 | globenewswire.comPlus Therapeutics Restructures Financing to Eliminate Potential Dilution of 1.5 Billion SharesJune 24, 2025 | quiverquant.comQPlus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity FinancingJune 24, 2025 | globenewswire.comPlus (PSTV) Upgraded to Buy: Here's WhyJune 19, 2025 | zacks.comPlus Therapeutics Modifies Security Holders’ RightsJune 17, 2025 | tipranks.comPlus Therapeutics Reports First Quarter Financial Results and Recent Business HighlightsMay 30, 2025 | finance.yahoo.comPlus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue EstimatesMay 30, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLFWD, COCH, PSTV, and CLGN Company DescriptionsCollPlant Biotechnologies NASDAQ:CLGN$2.33 -0.09 (-3.72%) Closing price 08/1/2025 03:57 PM EasternExtended Trading$2.31 -0.02 (-1.07%) As of 08/1/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.Envoy Medical NASDAQ:COCH$1.44 -0.02 (-1.03%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$1.46 +0.02 (+1.38%) As of 08/1/2025 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.Lifeward NASDAQ:LFWD$0.70 -0.01 (-1.00%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.70 +0.01 (+0.95%) As of 08/1/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.Plus Therapeutics NASDAQ:PSTV$0.58 +0.10 (+21.12%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.57 -0.02 (-3.08%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
